



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

April 2, 2025

Lewis H. Bender  
President, Chief Executive Officer and Chairman  
Intensity Therapeutics, Inc.  
1 Enterprise Drive, Suite 430  
Shelton, CT 06484-4779

**Re: Intensity Therapeutics, Inc.**  
**Draft Registration Statement on Form S-1**  
**Submitted March 28, 2025**  
**CIK No. 0001567264**

Dear Lewis H. Bender:

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement at least two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Joshua Gorsky at 202-551-7836 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences

cc: Ivan K. Blumenthal, Esq.